Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 19-26

  Biganzoli, L ^a   Aapro, M ^b   Loibl, Sibylle ^c   Wildiers, Hans ^d   Brain, Etienne ^e  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c SANA KLINIKUM OFFENBACH   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e INSTITUT CURIE   (France)

Author keywords

Breast cancer; Docetaxel; Elderly; Nab paclitaxel; Paclitaxel; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CABAZITAXEL; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; FLUOROURACIL; IXABEPILONE; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TAXANE; TAXOID;

ABDOMINAL PAIN; AGING; ALLERGY; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; DIARRHEA; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; REVIEW; SKIN TOXICITY; AGED; BREAST NEOPLASMS; CANCER STAGING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MEDICATION THERAPY MANAGEMENT; METABOLISM; PATHOLOGY; PSYCHOLOGY; QUALITY OF LIFE; RISK ASSESSMENT;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MEDICATION THERAPY MANAGEMENT; NEOPLASM STAGING; QUALITY OF LIFE; RECEPTOR, ERBB-2; RISK ADJUSTMENT; TAXOIDS;

EID: 84963649280     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.11.009     Document Type: Review

References (82)

1. http://seer.cancer.gov/statfacts/html/breast.html.
2. Ferlay J., Stellarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
3. Schonberg M.A., Mercantonio E.R., Li D., et al. Breast cancer among the oldest old: tumor characteristics, treatment choices and survival. J Clin Oncol 2010, 12:2038-2045.
4. Joerger M., Thurlimann B., Savidan A., et al. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2013, 4:39-47.
5. Silliman R.A. When cancer in older adults is undermanaged: the breast cancer story. J Am Geriatr Soc 2009, (Suppl. 2):S259-S261.
6. Kendal W.S. Dying with cancer. Cancer 2008, 112:1354-1362.
7. Wildiers H., Heeren P., Puts M., Topinkova E., Janssen-Heijnen M., et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014, 32:2595-2603.
8. https://data.un.org/DAta.aspatient?d=GenderStat%26f=inID%3A36.
9. Carlson R.W., Moench S., Hurria A., et al. NCCN Task Force Report: Breast cancer in the older woman. J Natl Comp Cancer Netw 2008, 6(Suppl. 4):S1-25.
10. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005, 353:1659-1672.
11. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
12. Early Breast Cancer Trialists' Collaborative Group Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012, 379:432-444.
13. Rosso S., Godos A., Zanetti R., et al. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 2010, 46:3351-3357.
14. Jatoi I., Chen B.E., Anderson W.F., Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007, 25:1683-1690.
15. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8:1101-1115.
16. Biganzoli L., Wildiers H., Oakman C., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012, 13:e148-e160. [Epub 2012 Mar 30].
17. Extermann M., Balducci L., Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients?. J Clin Oncol 2000, 18:1709-1717.
18. Wildiers H., Highley M.S., de Bruijn E.A., van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003, 42:1213-1242.
19. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients - an analysis of the medical literature. J ClinOncol 2007, 25:1832-1843.
20. Biganzoli L., Di Vincenzo E., Jian Z., et al. First-line bevacizumab-containing chemotherapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Ann Oncol 2012, 23:111-118.
21. Swain S., Whaley F., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
22. Pinder M., Dhuan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
23. Aapro M., Bernard-Marty C., Brain E.G., et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011, 22:257-267.
24. Bourgeois H., Soulié P., Lucas B., et al. ALOPREV: First cooling scalp trial for prevention of persisting alopecia after docetaxel for early breast cancer patients. Cancer Res 2012, 72(24 Suppl.). Abs OT3-3-04.
25. Wildiers H., Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004, 30:333-342.
26. Biganzoli B., Licitra S., Moretti E., et al. Taxanes in the elderly: can we gain as much and be less toxic?. Crit Rev Oncol Hematol 2009, 70:262-271.
27. tenTije T.A., Verweij J., Carducci M.A., et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005, 23:1070-1077.
28. Minami H., Ohe Y., Niho S., et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?. J Clin Oncol 2004, 22:2901-2908.
29. Lichtman S., Hollis D., Miller A.A., et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006, 24:1846-1851.
30. Smorenburg C.H., ten Tije A.J., Verweij J., et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003, 39:196-202.
31. Aapro M., Bohlius J., Cameron D.A., et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
32. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004, 15:1358-1365.
33. Rivera E., Mejia J.A., Arun B., et al. Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: final results. J Clin Oncol 2006, 24. Abs 574.
34. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642-1649.
35. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:113-1671.
36. Sparano J.A., Zhao F., Martino S., et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 2015, 10.1200/JCO.2015.60.9271.
37. Hainsworth J.D., Burris H.A., Yardley D.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001, 19:3500-3505.
38. Girre V., Rousseau E., Blot E., et al. Biweekly docetaxel as first-line chemotherapy regimen in elderly metastatic breast cancer patients with impact on autonomy as main endpoint. A FNCLCC GERICO GROUP phase II. Ann Oncol 2008, 19(Suppl. 8):viii208-viii210.
39. Perrone F, Nuzzo F, Di Rella F. et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2014 Dec 8.pii: mdu564. [Epub ahead of print].
40. Perez E.A., Vogel C.L., Irwin D.H., et al. Weekly paclitaxel in women aged 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002, 73:85-88.
41. Del Mastro L., Perrone F., Repetto L., et al. Weekly paclitaxel in women aged 65 and above with metastatic breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005, 16:253-258.
42. ten Tije A.J., Smorenburg C.H., Seynaeve C., et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer: a multicentre phase II trial. Eur J Cancer 2004, 40:352-357.
43. Beuselinck B., Wildiers H., Wynendaele W., et al. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol 2010, 75:70-77.
44. ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003, 42:665-685.
45. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor-oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
46. Gardner E.R., Dahut W.L., Scripture C.D., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14:4200-4205.
47. Hurria A., Blanchard M.S., Synold T.W., et al. Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist 2015, 20:37-44.
48. http:/meetinglibrary.asco.org/content/114428-132.
49. Perez-Valderrama B, Mellado B, Juan MJ et al. Preliminary results of a phase II study of weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer (MCRPC) patients progressing after docetaxel treatment (SOGUG-CABSEM TRIAL). Ann Oncol 2014;25 (Suppl 4):iv255-79.
50. Yared J.A., Tkaczuk K.H. Update on taxane development: new analogs and new formulations. Drug Des Dev Ther 2012, 6:371-384.
51. Lichtman S.M., Hurria A., Cirrincione C.T., et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9324 and 9840. Ann Oncol 2012, 23:6322-6328.
52. Lawton M.P., Brody E.M. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
53. Luciani A., Jacobsen P.B., Extermann M., et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008, 3424-3430.
54. Gradishar W.J. Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer. Oncol Hematol Rev 2013, 9:45-51.
55. Gradishar W.J., Krasnojon D., Cheporov S., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 22:3611-3619.
56. Untch M, Jackisch C, Schneeweiß A, Conrad B, Aktas B et al. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 SABCS 2014 [PD2-6].
57. Rugo HS, Barry WT, Moreno-Aspitia A et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015 [June 8 Epub ahead of print].
58. Aapro M., Tjulandin S., Bhar P., Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post hoc analysis. Breast 2011, 20:468-474.
59. Biganzoli L, Orlando L, Minisini A, et al. Evaluation of two different doses of weekly nab-paclitaxel in older breast cancer patients. J Clin Oncol 2015 [Suppl; abstract 9531].
60. Wildiers H., Mauer M., Pallis A., et al. End points and trial design in geriatric oncology research: a joint European Organisation for Research and Treatment of Cancer - Alliance for Clinical Trials in Oncology - International Society of Geriatric Oncology position article. J Clin Oncol 2013, 31:3711-3718.
61. Muss H.B., Berry D.A., Cirrincione C., et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 2007, 25:3699-3704.
62. Muss H.B., Berry D.A., Cirrincione C.T., et al. Adjuvant chemotherapy in older women with early stage breast cancer. N Engl J Med 2009, 360:2055-2065.
63. von Minckwitz G, Reimer T, Potenberg J et al. The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. San Antonio Breast Cancer Symposium 2014; Abstract S3-04.
64. Jones S., Holmes F.A., O'Shaughnessy J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27:1177-1183.
65. Freyer F., Campone M., Peron J., et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol 2011, 80:466-473.
66. Younus J., Vendenberg T., Jawaid M., Jawaid M.A. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice - an updated analysis. Curr Oncol 2012, 19:332-334.
67. Wildiers H., Brain E. Different adjuvant chemotherapy regimens in older breast cancer patients?. Ann Oncol 2015, 26:613-615.
68. Shulman L.N., Berry D.A., Cirrincione C.T., et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 2014, 32:2311-2317.
69. Loibl S, von Minckwitz G, Harbeck N et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German breast cancer trials. Br Cancer Res 2008; 10: Sep 16 doi 10.1186/bcr2144.
70. Barcenas C.H., Niu J., Zhang N., et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 2014, 32:2010-2017.
71. von Minckwitz G, Conrad B, Decker T, et al. ICE II: investigational chemotherapy in elderly patients. Final results from a randomized phase II study comparing epirubicin plus cyclophosphamide or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non-frail breast cancer patients with an increased risk of relapse. EBCC 2014 [Abs 228].
72. Russel S.D., Blackwell K.L., Lawrence J., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials. J Clin Oncol 2010, 28:3416-3421.
73. Bowles E.J.A., Wellman R., Feigelson H.S., et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012, 104:1293-1305.
74. Chen J., Long J.B., Hurria A., et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012, 60:2504-2512.
75. Chavez-MacGregor M., Zhang N., Buchholz T.A., et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013, 31:4222-4228.
76. Tsai H.A.T., Isaacs C., Fu A.Z., et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat 2014, 144:163-170.
77. Jones S.E., Collea R., Paul D., et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single group, open-label, phase 2 study. Lancet Oncol 2013, 14:1121-1128.
78. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
79. Tolaney S.M., Barry W.T., Deng C.T., et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2 positive breast cancer. N Engl J Med 2015, 372:134-141.
80. Lazzaro C., Bordonaro R., Cognetti F., et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcome Res 2013, 5:125-135.
81. Dranitsaris G., Yu B., King J., et al. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res 2015, 7:249-256.
82. Alba E., Ciruelos E., Lopez R., et al. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Rev Pharmacoeconom Outcome Res 2013, 13:381-391.